Researchers at Fox Chase Cancer Center have identified a biomarker that can predict how well individual colon cancer patients will respond to a common chemotherapy regimen. This finding is a significant step forward in the goal of personalizing cancer treatment. Medical oncologist Neal J. Meropol, M.D., director of the gastrointestinal cancer program at Fox Chase, presented the study today in New Orleans at the 40th Annual Meeting of the American Society of Clinical Oncology.
The study involves an enzyme that is important in activating capecitabine. Capecitabine is a commonly used oral chemotherapy drug that is converted into its active form by the enzyme thymidine phosphorylase (TP). TP is found in some, but not all, cancers. Capecitabine (marketed by Roche under the name Xeloda) in combination with irinotecan ( marketed by Pfizer under the name Camptosar) is a chemotherapy regimen being developed to treat advanced colon cancer patients.
Meropols study was designed to see if a correlation exists between how well a patient with metastatic colorectal cancer responds to chemotherapy with capecitabine plus irinotecan, and whether or not the amount of TP in the tumor predicted success with therapy. The study included 67 patients, ranging in age from 40 to 81, who had received no prior chemotherapy for their metastatic disease.
Karen C. Mallet | EurekAlert!
Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion
Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
24.10.2016 | Earth Sciences
24.10.2016 | Life Sciences
24.10.2016 | Physics and Astronomy